POP Biotechnologies, Inc.

Exhibitor

POP Biotechnologies, Inc. is a Buffalo, New York-based private biotechnology company developing next-generation vaccines and immunotherapies using proprietary porphyrin-phospholipid liposome technologies. Its lead platform, SNAP™ (Spontaneous Nanoliposome Antigen Particleization), uses cobalt-modified liposomes to rapidly assemble stable, highly immunogenic nanoparticle vaccines from his-tagged antigens. The company has achieved human clinical validation through the EuCorVac-19 COVID-19 vaccine program and has expanded the platform into influenza, RSV, herpes zoster, Alzheimer’s immunotherapy, and epidemic preparedness programs, including a CEPI-supported Disease X initiative. POP BIO’s strategy is to apply a modular nanoliposome platform across multiple therapeutic and vaccine indications through internal development and external collaborations.